Xiaofei Wang1, Wenli Cheng2, Jingdong Li2, Anping Su2, Tao Wei2, Feng Liu2, Jingqiang Zhu3. 1. Department of Thyroid and Breast SurgeryWest China Hospital, Sichuan University, Chendu 610041, ChinaDepartments of General SurgeryOtolaryngology-Head and Neck SurgeryAffiliated Hospital of North Sichuan Medical College, Nanchong 637000, China Department of Thyroid and Breast SurgeryWest China Hospital, Sichuan University, Chendu 610041, ChinaDepartments of General SurgeryOtolaryngology-Head and Neck SurgeryAffiliated Hospital of North Sichuan Medical College, Nanchong 637000, China. 2. Department of Thyroid and Breast SurgeryWest China Hospital, Sichuan University, Chendu 610041, ChinaDepartments of General SurgeryOtolaryngology-Head and Neck SurgeryAffiliated Hospital of North Sichuan Medical College, Nanchong 637000, China. 3. Department of Thyroid and Breast SurgeryWest China Hospital, Sichuan University, Chendu 610041, ChinaDepartments of General SurgeryOtolaryngology-Head and Neck SurgeryAffiliated Hospital of North Sichuan Medical College, Nanchong 637000, China westchinaz@sohu.com.
Abstract
OBJECTIVE: There is controversy as to whether familial nonmedullary thyroid carcinoma (FNMTC) is more aggressive than sporadic NMTC (SNMTC). The aim of the study was to evaluate the biological characteristics of patients with FNMTC by a meta-analysis. METHODS: Four databases (PubMed, EMBASE, the Cochrane library databases, and the Web of Science) were searched to identify studies published before September, 2014. All original studies that compared clinical characteristics and prognosis of patients with FNMTC and SNMTC were included. The pooled effect sizes of interesting parameters were calculated by odds ratio (OR), standard mean difference (SMD), or hazard ratio (HR). RESULTS: Twelve studies with a total of 12 741 participants were included in this analysis. FNMTC patients had an increased rate of recurrence (OR=1.72, 95% CI: 1.34 to 2.20) and decreased disease-free survival (DFS) (HR=1.83, 95% CI: 1.34 to 2.52) in comparison with SNMTC patients. FNMTC possessed more aggressive biological behaviors, characterized by younger age at diagnosis (SMD=-0.91, 95% CI: -1.59 to -0.22), higher risk of multifocal (OR=1.50, 95% CI: 1.32 to 1.71), bilateral (OR=1.29, 95% CI: 1.00 to 1.66), extrathyroidal invasion (OR=1.20, 95% CI: 1.02 to 1.41), and lymph node metastasis (OR=1.18, 95% CI: 1.01 to 1.38). CONCLUSION: FNMTC is a more aggressive disease and possesses higher recurrence rate and lower DFS. More attention and careful consideration should be paid regarding the decision about treatment for patients with FNMTC.
OBJECTIVE: There is controversy as to whether familial nonmedullary thyroid carcinoma (FNMTC) is more aggressive than sporadic NMTC (SNMTC). The aim of the study was to evaluate the biological characteristics of patients with FNMTC by a meta-analysis. METHODS: Four databases (PubMed, EMBASE, the Cochrane library databases, and the Web of Science) were searched to identify studies published before September, 2014. All original studies that compared clinical characteristics and prognosis of patients with FNMTC and SNMTC were included. The pooled effect sizes of interesting parameters were calculated by odds ratio (OR), standard mean difference (SMD), or hazard ratio (HR). RESULTS: Twelve studies with a total of 12 741 participants were included in this analysis. FNMTC patients had an increased rate of recurrence (OR=1.72, 95% CI: 1.34 to 2.20) and decreased disease-free survival (DFS) (HR=1.83, 95% CI: 1.34 to 2.52) in comparison with SNMTC patients. FNMTC possessed more aggressive biological behaviors, characterized by younger age at diagnosis (SMD=-0.91, 95% CI: -1.59 to -0.22), higher risk of multifocal (OR=1.50, 95% CI: 1.32 to 1.71), bilateral (OR=1.29, 95% CI: 1.00 to 1.66), extrathyroidal invasion (OR=1.20, 95% CI: 1.02 to 1.41), and lymph node metastasis (OR=1.18, 95% CI: 1.01 to 1.38). CONCLUSION: FNMTC is a more aggressive disease and possesses higher recurrence rate and lower DFS. More attention and careful consideration should be paid regarding the decision about treatment for patients with FNMTC.
Authors: Mustapha El Lakis; Andreas Giannakou; Pavel J Nockel; Douglas Wiseman; Sudheer Kumar Gara; Dhaval Patel; Zahraa Abdul Sater; Yevgeniya Y Kushchayeva; Joanna Klubo-Gwiezdzinska; Naris Nilubol; Maria J Merino; Electron Kebebew Journal: Surgery Date: 2018-10-14 Impact factor: 3.982
Authors: A Ríos; M A Rodríguez; J A Puñal; P Moreno; E Mercader; E Ferrero; J Ruiz-Pardo; M A Morlán; J Martín; M Durán-Poveda; J M Bravo; D Casanova; M P Salvador Egea; N M Torregrosa; A Exposito-Rodríguez; G Martínez-Fernández; A M Carrión; O Vidal; F Herrera; G Ruiz-Merino; J M Rodríguez Journal: Langenbecks Arch Surg Date: 2022-10-17 Impact factor: 2.895
Authors: I J Nixon; C Suárez; R Simo; A Sanabria; P Angelos; A Rinaldo; J P Rodrigo; L P Kowalski; D M Hartl; M L Hinni; J P Shah; A Ferlito Journal: Eur J Surg Oncol Date: 2016-08-11 Impact factor: 4.424